Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
Circulation · 04.03.2025 · 151 (9) · 589-600
DOI: 10.1161/circulationaha.124.072758 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation, erschienen am 04.03.2025. Verfasst von Yugo Yamashita und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y.Y., K.O.). Hauptthemen laut MEDLINE: Rivaroxaban, Pulmonary Embolism, Neoplasms, Factor Xa Inhibitors. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 32 institutions in Japan, we randomly assigned patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, in a 1:1 ratio, to receive either an 18-month or a 6-month rivaroxaban treatment. The primary end point was recurrent venous thromboembolism (VTE) at 18 months. The major secondary end point was major bleeding at 18 months according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that an 18-month treatment was superior to a 6-month treatment in terms of the primary end point. RESULTS: From February 2021 to March 2023, 179 patients were randomized, and after the exclusion of one patient who withdrew consent, 178 were included in the intention-to-treat population: 89 patients in the 18-month rivaroxaban group and 89 in the 6-month rivaroxaban group. The mean age was 65.7 years; 47% of the patients were men, and 12% had symptoms of PE at baseline. The primary end point of recurrent VTE occurred in 5 of the 89 patients (5.6%) in the 18-month rivaroxaban group and in 17 of the 89 (19.1%) in the 6-month rivaroxaban group (odds ratio, 0.25 [95% CI, 0.09–0.72]; P =0.01). Among 22 recurrent VTE, 5 patients presented with a symptomatic recurrent VTE; recurrent PE occurred in 11 patients, including 2 with main and 4 with lobar PEs; and recurrent deep vein thrombosis was seen in 11 patients, including 3 with proximal deep vein thromboses. The major secondary end point of major bleeding occurred in 7 of the 89 patients (7.8%) in the 18-month rivaroxaban group and in 5 of the 89 patients (5.6%) in the 6-month rivaroxaban group (odds ratio, 1.43 [95% CI, 0.44–4.70]; P =0.55). CONCLUSIONS: In patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, the 18-month rivaroxaban treatment was superior to the 6-month rivaroxaban treatment with respect to recurrent VTE events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04724460.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y.Y., K.O.).
- Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan (T.M.).
- Division of Cardiology, Shizuoka Cancer Center, Japan (N.M.).
- Department of Cardiovascular Medicine, Shiga University of Medical Science, Japan (W.S.).
- Department of Cardiovascular Medicine, Kurashiki Central Hospital, Japan (R.C.).
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Japan (T. Shibata).
ORCID-Profile: Yugo Yamashita, Takeshi Morimoto, Wataru Shioyama, Ryuki Chatani, Tatsuhiro Shibata, Yuji Nishimoto, Yoshito Ogihara, Kosuke Doi, Maki Oi, Daisuke Sueta, Yasuhiro Tanabe, Norimichi Koitabashi, Satoshi Ikeda, Hitoshi Nakagawa, Naohiko Nakanishi, Kazuhisa Kaneda, Koh Ono, Takeshi Kimura
Zitieren
APA
Yamashita, Y., Morimoto, T., Muraoka, N., Shioyama, W., Chatani, R., Shibata, T., Nishimoto, Y., Ogihara, Y., Doi, K., Oi, M., Shiga, T., Sueta, D., Kim, K., Tanabe, Y., Koitabashi, N., Takada, T., Ikeda, S., Nakagawa, H., Tsukahara, K., …, & ONCO PE Trial Investigators (2025). Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). Circulation, 151(9), 589-600. https://doi.org/10.1161/circulationaha.124.072758
Vancouver
Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Chatani R, Shibata T, et al. Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). Circulation. 2025;151(9):589-600. doi:10.1161/circulationaha.124.072758
BibTeX
@article{Yamashita2025,
author = {Yamashita, Yugo and Morimoto, Takeshi and Muraoka, Nao and Shioyama, Wataru and Chatani, Ryuki and Shibata, Tatsuhiro and Nishimoto, Yuji and Ogihara, Yoshito and Doi, Kosuke and Oi, Maki and Shiga, Taro and Sueta, Daisuke and Kim, Kitae and Tanabe, Yasuhiro and Koitabashi, Norimichi and Takada, Takuma and Ikeda, Satoshi and Nakagawa, Hitoshi and Tsukahara, Kengo and Shoji, Masaaki and Sakamoto, Jiro and Hisatake, Shinji and Ogino, Yutaka and Fujita, Masashi and Nakanishi, Naohiko and Dohke, Tomohiro and Hiramori, Seiichi and Nawada, Ryuzo and Kaneda, Kazuhisa and Ono, Koh and Kimura, Takeshi and ONCO PE Trial Investigators, ONCO PE Trial Investigators},
title = {Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)},
journal = {Circulation},
year = {2025},
volume = {151},
number = {9},
pages = {589--600},
doi = {10.1161/circulationaha.124.072758}
}
EUVIMED